Étiquette : essais clinique

A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential, C. Michael White, 2019

A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential C. Michael White The Journal of Clinical Pharmacology, 2019, 59, (7) 923–934 Doi : 10.1002/jcph.1387   Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA) approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.The legal status of the non–FDA approved products differs depending on the source of the CBD and the state,while the consistency and quality of the non–FDA-approved [...]

Lire la suite

Long-term effects of psychedelic drugs : A systematic review, Jacob S.Aday et al., 2020

Long-term effects of psychedelic drugs : A systematic review Jacob S.Adaya, Cayla M.Mitzkovitz, Emily K.Bloesch, Christopher C.Davoli, Alan K.Davis Neuroscience and Biobehavioral Reviews, 2020. Doi : 10.1016/j.neubiorev.2020.03.017   A B S T R A C T Research into the basic effects and therapeutic applications of psychedelic drugs has grown considerably in recent years. Yet, pressing questions remain regarding the substances’ lasting effects. Although individual studies have begun monitoring sustained changes, no study to-date has synthesized this information. Therefore, this systematic review aims to fill this important gap in the literature by synthesizing results from 34 contemporary experimental studies which included classic psychedelics, human subjects, and follow-up [...]

Lire la suite

La FDA accélère la recherche sur la psilocybine pour les troubles dépressifs majeurs, Aurélien Bernard, 2019

La FDA accélère la recherche sur la psilocybine pour les troubles dépressifs majeurs   Aurélien Bernard Newsweed, 28 novembre 2019 https://www.newsweed.fr/fda-accelere-recherche-psilocybine-depression/     La Food and Drug Administration (FDA) a catégorisé les champignons hallucinogènes en tant que « thérapie révolutionnaire » pour les troubles dépressifs majeurs (MDD), une démarche qui accélérera la recherche de nouveaux médicaments à partir de psilocybine. Cette classification a été créée en 2012 pour encadrer les recherches et le développement produit de médicaments à partir de susbtances ayant un potentiel fort par rapport aux options existantes et pour des patients atteints de maladie grave ou qui met leur vie en danger. La première recherche [...]

Lire la suite

Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962, Matthew ORAM, 2012

Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962 Matthew ORAM Journal of the History of Medicine and Allied Sciences, 2012, Volume 69, Number 2, 221-250. doi:10.1093/jhmas/jrs050   ABSTRACT. The decline in therapeutic research with lysergic acid diethylamide (LSD) in the United States over the course of the 1960s has commonly been attributed to the growing controversy surrounding its recreational use. However, research difficulties played an equal role in LSD psychotherapy’s demise, as they frustrated researchers’ efforts to clearly establish the efficacy of treatment. Once the Kefauver Harris Drug Amendments of 1962 introduced the requirement that proof of efficacy be established through controlled clinical [...]

Lire la suite

Ibogaine : A review – Chapter 1, Kenneth R. Alper, 2001

Ibogaine : A review - Chapter 1 Kenneth R. Alper The Alkaloids. Chemistry and Biology, 2001, 56,  38 pp DOI: 10.1016/S0099-9598(01)56005-8   I. Introduction, Chemical Properties, and Historical Time Line ..................... A. Introduction................................................................................................... B. Chemical Structure and Properties .............................................................. C. Historical Time Line ..................................................................................... II. Mechanisms of Action .................................................................................. A. Neurotransmitter Activities........................................................................... B. Discrimination Studies.................................................................................. C. Effects on Neuropeptides............................................................................... D. Possible Effects on Neuroadaptations Related to Drug Sensitization or Tolerance ....................................................................................................... III. Evidence of Efficacy in Animal Models........................................................ A. Drug Self-Administration .............................................................................. B. Acute Opioid Withdrawal .............................................................................. C. Conditioned Place Preference........................................................................ D. Locomotor Activity........................................................................................ E. Dopamine Efflux............................................................................................. IV Evidence of Efficacy and Subjective Effects in Humans .............................. A. Evidence of Efficacy........................................................................................ B. Subjective Effects ........................................................................................... V. Pharmacokinetics ........................................................................................... A. Absorption....................................................................................................... B. Distribution .................................................................................................... C. Metabolism .................................................................................................... D. Excretion [...]

Lire la suite

Ayahuasca Scientific Papers, AEDMP, 2013

Ayahuasca Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Genís Oña -2013- Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org   Content _____________________________________ 1. What is ayahuasca? 2. Scientific papers about ayahuasca arranged chronologically (1969-2013) - G. R. Dolmatoff (1969). El contexto cultural de un alucinógeno aborigen : Banisteriopsis Caapi - C. Grob et al. (1996). Human Psychopharmacology of Hoasca, a Plant Hallucinogen Used in Ritual Context in Brazil - J. C. Callaway et al. (1999). Pharmacokinetics of Hoasca Alkaloids in Healthy Humans - B. Shanon (2000). Ayahuasca and [...]

Lire la suite

Pharmacology of Consciousness or Pharmacology of Spirituality ? A Historical Review of Psychedelic Clinical Studies, Ismael Apud, 2016

Pharmacology of Consciousness or Pharmacology of Spirituality ? A Historical Review of Psychedelic Clinical Studies Ismael Apud The Journal of Transpersonal Psychology, 2016, Vol. 48, No. 2, 150-167.   ABSTRACT: In the second half of the twentieth century, when psychopharmacology was not developed as we know it today and psychoanalysis was an influential school, various psychiatrists began to develop a ‘pharmacology of consciousness,’ and became interested in hallucinogens as new paths for accessing the unconscious. However, with the psychedelic model, the pharmacology of consciousness turned also into a ‘pharmacology of spirituality,’ focused on the use of spiritual experiences as catalyzers of psychological change. This article [...]

Lire la suite

Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark, Jens Knud Larsen, 2016

Neurotoxicity and LSD treatment : a follow-up study of 151 patients in Denmark Jens Knud Larsen University Hospital of Aarhus, Risskov, Denmark History of Psychiatry, 2016, Vol. 27, (2), 172–189 DOI: 10.1177/0957154X16629902   Abstract LSD was introduced in psychiatry in the 1950s. Between 1960 and 1973, nearly 400 patients were treated with LSD in Denmark. By 1964, one homicide, two suicides and four suicide attempts had been reported. In 1986 the Danish LSD Damages Law was passed after complaints by only one patient. According to the Law, all 154 applicants received financial compensation for LSD-inflicted harm. The Danish State Archives has preserved the case material of 151 [...]

Lire la suite

Motives and Side-Effects of Microdosing With Psychedelics Among Users, Nadia R. P. W. Hutten et al., 2019

Motives and Side-Effects of Microdosing With Psychedelics Among Users Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers International Journal of Neuropsychopharmacology, 2019, 1–9 doi:10.1093/ijnp/pyz029   Abstract Background : Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects. Methods : An [...]

Lire la suite

Bibliographie Cannabinoïdes et autismes , GRECC, Dr Christian Sueur, mars 2019

Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles. Dr Christian Sueur, GRECC, mars 2019. (2e version) ARAN A., CASSUTO H., LUBOTZKY : Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasability Study (P3.318), Neurology Genetics, 2018, 90 (15). http://n.neurology.org/content/90/15_Supplement/P3.318 ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasability Study, Journal of Autism and Developmental Disorders, 2018 Oct 31. Doi : 10.1007/s10803-018-3808-2 BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. : Oral Cannabidiol Use in Children With Auttism Spectrum Disorder to Treat Related Symptoms [...]

Lire la suite